An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.
about
Usutu virus: an emerging flavivirus in EuropeFeasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplexJapanese encephalitis: the virus and vaccinesAdvax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvantDelta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza VaccineAdvax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protectionAdvax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety.Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvantThe polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions.Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.Development of a Japanese encephalitis virus-like particle vaccine in silkworms using codon-optimised prM and envelope genes.Gamma ray sterilization of delta inulin adjuvant particles (Advax™) makes minor, partly reversible structural changes without affecting adjuvant activity.A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protectionNo evidence of murine leukemia virus-related viruses in live attenuated human vaccines.The chemokine receptor CCR5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitisImmunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulationsSafety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foalsPivotal role of antibody and subsidiary contribution of CD8+ T cells to recovery from infection in a murine model of Japanese encephalitisDelta inulin: a novel, immunologically active, stable packing structure comprising β-D-[2 -> 1] poly(fructo-furanosyl) α-D-glucose polymers.Carbohydrate-based immune adjuvants.Technologies for enhanced efficacy of DNA vaccines.Recombinant Measles AIK-C Vaccine Strain Expressing the prM-E Antigen of Japanese Encephalitis Virus.Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future NeedsConstruction and immune efficacy of recombinant pseudorabies virus expressing PrM-E proteins of Japanese encephalitis virus genotype І.The future of human DNA vaccinesApplications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibodyAn inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibodyDelta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.Natural exposure of horses to mosquito-borne flaviviruses in south-east Queensland, Australia.Internal ribosome entry site-based attenuation of a flavivirus candidate vaccine and evaluation of the effect of beta interferon coexpression on vaccine propertiesIn planta production of plant-derived and non-plant-derived adjuvants.Immunological aspects of using plant cells as delivery vehicles for oral vaccines.Carbohydrate-based vaccine adjuvants - discovery and development.Implications of plant glycans in the development of innovative vaccines.Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection.Memory B cells: a proposed new immunological correlate for protective efficacy of Japanese encephalitis vaccine.
P2860
Q24273302-81E0AACD-141E-4544-9F3C-7EC8C252C2F2Q24737461-E06BC5F3-8F18-458C-A83B-E341B56285DCQ27010434-18F9AB8C-000A-4EC3-8B74-4E09738332DFQ28384323-B8E433C3-4E1C-4BE7-A894-1DC43DA9E667Q30376743-7F3F18E0-DA4C-4C34-9429-122A050759A1Q30377381-A521AB4E-6A6A-40B4-99B5-E0DF5146CD53Q30379559-35C5CA44-597F-4F84-85F8-8B77A9F1D453Q30418297-C9AB667B-34A8-487A-8922-AEF8F0FC2E40Q30655287-A5F57B70-3410-48DB-93F9-911C5BF004A1Q33396140-462E2472-9A17-4728-922A-02B1C1A340DDQ33561655-908C3EE6-57E5-47BB-84C1-06F220319D94Q33718615-CDE2CC20-AC4F-413F-9A32-47857B311D3EQ33940730-298F3735-F89E-43F3-9C2E-B55890726D8BQ34117367-C26AEA61-3AE8-4A38-B69A-135A8491F7C2Q34427503-F8DDBF2E-8F65-497F-92CE-4FE653108363Q34621859-3FE42F1B-D8B9-4701-9514-1107484B7CD6Q34641666-BA33E417-8B75-468A-B77F-9EABACF3CB0BQ34720701-6401765F-4114-4660-BB25-37A7F76954A7Q34982611-13D7AF4B-8C44-4E1A-9DD7-7417BF03D17FQ35020296-99A0FEE2-0E22-4F18-BBBC-268037930758Q35054845-9494DAEF-5D4E-46AB-B766-76C9F7EA47CAQ35802958-3B1BF0C3-0AC6-4CD4-851E-0509E67BC6B0Q35941078-197A5DE1-1287-47F4-BF30-19EDDE767808Q36106655-44406454-58E3-433F-A40B-ADA36B65C482Q36191001-D949C7CE-58E7-4163-9283-DF805CF159A8Q36364196-51FF8B8D-C683-4F9F-8EAB-8F04F9A4E405Q36438236-C1DF6278-28E8-4CD4-98FA-6334F43D0E67Q36591050-78755B6F-9665-4817-A481-28DA451EC5EBQ36711264-EBE8764E-6925-4129-B2F9-0662B7B9A46FQ36760059-EDA2916A-5246-4440-961D-FF8F4A3CA278Q37123147-8A1480D0-4DA9-436F-B6CA-5507ED9182D0Q37197103-D32D8A9B-AA53-4F3C-9E3F-5E43BF1E4E98Q37236964-2F0989B6-7A53-4134-ADF9-D4691CD19775Q37547088-FDFFA085-6CD1-413A-853D-9E0FDDCD0A68Q37776716-E18A6822-9B13-4673-96DA-E54D37E18B51Q38207131-A7D1C13C-6D84-47A7-A2FA-7A9C26DA8307Q38587300-55DA9061-75C4-4522-B9BF-89FFB880D699Q38738762-A28CF003-3E5F-41B2-A3EB-2898F07BC1B8Q40089069-412BFD21-5CE3-4D84-8F70-2AA71FA3E00CQ40237994-7524A5CF-0226-40BD-8550-CF58E350E627
P2860
An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
An inactivated Vero cell-grown ...... and heterologous flaviviruses.
@ast
An inactivated Vero cell-grown ...... and heterologous flaviviruses.
@en
type
label
An inactivated Vero cell-grown ...... and heterologous flaviviruses.
@ast
An inactivated Vero cell-grown ...... and heterologous flaviviruses.
@en
prefLabel
An inactivated Vero cell-grown ...... and heterologous flaviviruses.
@ast
An inactivated Vero cell-grown ...... and heterologous flaviviruses.
@en
P2093
P2860
P356
P1476
An inactivated Vero cell-grown ...... and heterologous flaviviruses.
@en
P2093
Hiroko Toriniwa
Mario Lobigs
Megan Pavy
Peter Cooper
Päivi Lobigs
Roy A Hall
Tomoyoshi Komiya
P2860
P304
P356
10.1099/VIR.0.019190-0
P407
P577
2010-02-03T00:00:00Z